SAN CARLOS, Calif. (July 7, 2005) – Conceptus, Inc. (Nasdaq: CPTS), today announced that it has accelerated its efforts to market the Essure® procedure into physicians’ offices by entering into preferred relationships with two leading hysteroscope manufacturers, KARL STORZ Endoscopy America, Inc. and Richard Wolf Medical Instruments Corporation. The relationships will better promote the delivery of hysteroscopy services in doctors’ offices throughout the United States. These two manufacturers, with a combined 170 sales representatives, together account for 64% of the U.S. market for hysteroscopes, according to Millennium Research.

As part of these agreements, the Conceptus sales force will be equipped with small diameter hysteroscopes from both manufacturers, which will be used in the demonstration and training of the Essure procedure.

“These partnerships are very rewarding for everyone involved—physicians, patients and payers,” said Mark Sieczkarek, president and CEO of Conceptus. “The in-office setting provides an efficient site of service, which is more convenient for the patient and physician, while taking significant costs out of the healthcare system.”

Mr. Sieczkarek continued, “The new CPT code issued this year includes reimbursement for in-office Essure procedures, making this a viable financial alternative for physicians. We are looking forward to working with physicians who want to make this paradigm shift in female permanent birth control available to their patients.”

High levels of patient satisfaction are reported when minimally invasive surgical procedures are performed in an office setting. Gynecologists cite high levels of satisfaction specifically with the Essure procedure in office because of decreased office–to-hospital travel time, convenience in patient scheduling and patient comfort in a familiar setting.

“KARL STORZ Endoscopy is pleased to join Conceptus in promoting office-based hysteroscopy procedures performed by gynecologists,” said Thomas Prescher, Director of Marketing, Gynecology and Video, KARL STORZ. “This important collaboration is supportive of our company’s ongoing efforts to broaden the range of quality care patients can receive within the familiar atmosphere of their doctor’s office.”

“We are excited to partner with Conceptus, an innovator, and developer of the Essure hysteroscopic sterilization procedure. Together, our dedicated employees can deliver a powerful combination of products, education, and service to the gynecology community,” said Kevin Gallagher, Corporate Director of Sales and Marketing, Richard Wolf Medical Instruments Corporation.

About the Essure Procedure
The Essure procedure deploys a soft micro-insert into the fallopian tube through the cervix using a minimally invasive transcervical tubal access catheter. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or blockage in the fallopian tube. An Essure procedure does not require cutting or penetrating the abdomen and can be performed in a less costly procedure setting without general anesthesia. A woman is able to return home about 45 minutes after the procedure is completed. There is a three-month waiting period after the procedure during which women must use another form of birth control. Essure is 99.80% effective after three years of follow-up.

About Conceptus Incorporated
Conceptus, Inc. manufactures and markets Essure, an innovative medical device and procedure, designed to provide a non-incisional alternative to tubal ligation, which is the leading form of birth control worldwide. The availability of Essure in the U.S. is expected to open up a market currently occupied by incisional tubal ligation and vasectomy, which combined account for over 1 million procedures annually.

Additional information about the Essure procedure is available at www.essure.com or by calling the Essure Information line at 1-877-ESSURE1. Additional information about Conceptus is available at www.conceptus.com or by calling 1-877-ESSURE2.

About KARL STORZ Endoscopy America, Inc.
Karl Storz Endoscopy America is the wholly owned subsidiary of Karl Storz GmbH & Co, Inc, Tuttlingen, Germany. Karl Storz is world renowned for the design, development and manufacture of optics, instrumentation and electronics for the multi-specialty surgical marketplace and takes great pride in serving these markets for 60 years. Karl Storz Sports Medicine has been formed to dedicate focus to the arthroscopic surgeon and his unique needs. For more information, please visit www.karlstorz.com.

About Richard Wolf Instruments Incorporated
Richard Wolf is a market leader in producing quality instrumentation and visualization equipment for the gynecology surgical market. Richard Wolf Medical Instruments Corporation (RWMIC), a subsidiary of the German based Richard Wolf GmbH is located in the heart of the Midwest just north of Chicago and services the entire United States. Its modern facility in Vernon Hills, IL houses manufacturing, marketing, repair, customer service, and administration functions. The mission of Richard Wolf GmbH is to advance the science of endoscopy through the continual support of research with leading universities and physicians. Richard Wolf serves a broad range of endoscopic surgical specialties. Leading surgeons the world-over work with Richard Wolf to develop endoscopic innovations. As a result, Richard Wolf has pioneered many endoscopic products and procedures.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Discussions regarding hysteroscopy partnerships and our ability to promote in-office procedures, among other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be based upon factors such as strategic planning decisions by management, re-allocation of internal resources, decisions by insurance companies, scientific advances by third parties, and introduction of competitive products, as well as those factors set forth in the Company's most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q, and other filings with the Securities and Exchange Commission.